Výsledky vyhledávání - "Daniel Ricardo Carrizosa"

Figure S5. Tumor Epithelial/Stromal Compartment CD8+ T-Cell Ratio in Tissue-Matched Metastatic Tumors (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Baseline (screening) vs treatment cycle 2 (P=.06; paired t test). For patient 5, baseline data were not available.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd98b63eb49f579d01cbe44a0a85231
https://doi.org/10.1158/1078-0432.22475423

Zobrazit plný text záznamu

Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Purpose:Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial.Patients and Methods:Fifty chemotherapy-naive patients receive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91944ff29f7b99aa8e56f618a1dd6950
https://doi.org/10.1158/1078-0432.c.6529076.v1

Zobrazit plný text záznamu

Figure S3. Peripheral T-Cell Proliferation on Treatment (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Percentage lymphocyte subset Ki67+. All patient visits are binned by treatment cycle. Data at baseline and treatment cycle 3 were compared using the Wilcoxon signed rank test. All available data are illustrated; however, statistical comparisons were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af451ccc2b3f88d0ca2643cefe85947
https://doi.org/10.1158/1078-0432.22475429

Zobrazit plný text záznamu

Figure S4 from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

T-Cell Tumor Infiltration in Tissue-Matched Baseline (screening) and On-Treatment Metastatic Tumors (arm B parts 1 and 2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5462aa83ef7e3c2c1c1145183bef1b4
https://doi.org/10.1158/1078-0432.22475426

Zobrazit plný text záznamu

Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Investigator-assessed PFS and OS in patients with PD-L1 expression cutoff of 1% (A, B) or 5% (C, D). HR, hazard ratio; mo, months; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e9db745e67db99e4742619e1ece12c
https://doi.org/10.1158/1078-0432.22475435.v1

Zobrazit plný text záznamu

Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898ef1dea38981f86f8ebf1a7d51ab9a
https://doi.org/10.1158/1078-0432.22475438

Zobrazit plný text záznamu

Figure S6. Serum Cytokines (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Concentrations of CXCL10 (A) and sIL2Rα (B) at baseline and peak on-treatment values. Investigator-assessed PFS in patients with high or low serum cytokines CXCL10 (C) and sIL2Rα (D). CXCL10, interferon gamma-induced protein 10; mo, months; NE, not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b40b6e000cad2b036744f48c00548a3
https://doi.org/10.1158/1078-0432.22475420.v1

Zobrazit plný text záznamu

Supplementary Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Data Tables

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::647d7db3c6ca7c20467ff73cc4468883
https://doi.org/10.1158/1078-0432.22475417

Zobrazit plný text záznamu

Open-label, Phase I Study of Nivolumab Combined with

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 26(18)

Assess safety and efficacy of nivolumab plusFifty chemotherapy-naive patients receivedOne DLT (hepatitis) was reported in part 1 among six DLT-evaluable patients; 48 of 50 patients experienced grade 3/4 TEAEs and 18 discontinued treatment due to TEAE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a44d6bbcf116dda625f5c327a64e637
https://pubmed.ncbi.nlm.nih.gov/32554514

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání